Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

The growing influence of digital pathology in preclinical R&D: Spotlight on Proscia’s Concentriq

By Author Proscia | May 3, 2023

As drug discovery evolves, digital pathology platforms are playing a vital role in streamlining preclinical R&D processes and accelerating drug discovery. Proscia‘s Concentriq for Research reflects this trend. To learn more about Proscia’s digital pathology technology, we caught up with Nathan Buchbinder, co-founder and chief product officer at Proscia, who discussed how the Concentriq for Research digital pathology platform streamlines the preclinical R&D process and accelerates studies.

Our website uses cookies. By using this site, you agree to its use of cookies.